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Hitherto the erroneous activation and inactivation of signalling pathways are characteristic in human cancers. The connectivity of these pathways remains a central tenet of the prostate biology. The ‘sense’ in which they operate will provide insights into disease and novel avenues for the development of direct, non-cytotoxic interventions. The Protein Kinase C (PKC) superfamily continues to be a major element in prostate neoplasia as a family of targets for classes of tumour promoters and lipid-dependent. 

The complexity of PKC involvement in critical regulatory processes within different cell-systems has long been apparent. However, certain principles controlling the activity of different members of the PKC family have only emerged recently. The domain-specific locations of the autophosphorylation sites on PKC’s are indicative of distinct roles Amongst the almost twelve members of the family, the novel PKC- is organizing stochastic signalling pathways with c-Raf-1/PKC- displaying characteristic morphological properties of malignant transformation (Cacace AM et. al. 1996, Hamilton M. 2001). PKC- has been implicated in the traffic of β1-integrins from an intracellular recycling compartment through vimentin oligomerisation (Ivaska J 2005). 

Inappropriate activity of this protein, alone, appears to be sufficient to promote cells transformation from the benign to neoplastic phenotype. In androgen dependent LNCaP cells, overexpression of PKC- contribute to androgen independent expansion in absence of testicular androgens (Wu D 2002 Henttu P 1998). PKC- has been linked to anti-apoptotic programmes, but the molecular details of the downstream pathway(s) remain largely unknown. The oncogenic potential of the PKC- in response to a variety of stimuli appears to regulate transcription of proto-oncogene, transcription factors, metabolic pathways, apoptosis, and actin cytoskeleton rearrangement (Cacace AM et. al. 1993, Li Y. 1996, Ricky D. 2002, Franklin RB 2000, 1997).



























3.1.1. RNA Expression level of the PKC- is increased in human prostate cancer cells.
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To further study the mRNA levels of PKC- expressed in benign and malignant prostate epithelial cells, Northern Blotting hybridisation and Real-Time RT-PCR were employed to make quantitative assessment of the mRNA levels.  


3.1.2. Western Blot analysis of the levels of PKC- protein expression in benign and malignant prostate epithelial cell lines

Protein extracts prepared from different cell lines were subjected to Western blot analysis to measure the levels of PKC- protein (Figure 3.1.2.A.). Liver Hela cell line was used as appositive control and the β-actin antibody was used to correct the possible loading artefact. Western blot analysis detected a clear PKC- band with a size of 80 kDa (pointed by the arrow in the figure) in all cell lines examined. Quantitative analysis of the levels in different cell lines was obtained by measuring the intensities of the bands on the blot. The relative levels of PKC- protein expressed in each cell line was shown in Figure 3.1.2.B.  
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3.1.3. Suppression of PKC- expression by RNA interference

To study the biological significance of the increased PKC- expression in prostate cancer cells and particularly to investigate whether the elevated PKC- expression  plays an important role in promoting the malignant progression of prostate cancer cells, RNA interference was used to establish transfectant clones, in which the expression of PKC-  in the highly malignant prostate cancer cells was blocked.  The effect of suppressing PKC- expression on tumourigenicity of the recipient cells was assessed by comparing the malignant characteristics between the control and the PKC--suppressed cells.  

To suppress PKC- expression by RNAi, two short interference molecules was synthesized as described in the method section. Before performing stable DNA transfection, transient transfection of highly malignant Du-145 and PC3M cells with two selected RNAi molecules either singly or jointly to identify the most effective way to inhibit the PKC- expression. The levels of PKC- expression in different cell lines were assessed by Western blotting analysis. 

The results from Western blot analysis of the transient transfection of RNAi molecule-1 was shown in Figure 3.1.3.i.A. and 3.1.3.i.B. When the short RNAi molecule-1 was transfected into Du-145 cells and PC3M cells respectively, it produced a very small reduction 40% and 45% respectively in the level of PKC- protein expression. 
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Figure 3.1.3.ii. Western blotting analysis was verified the relative PKC- protein reduction levels with siRNA molecule 2 in both DU 145 cells (A) and PC3M cells(B). 













Amongst the 10 transfectant clones, the levels of PKC- expression were reduced by 40-85% (or 15% to 60% of the level detected in the control cells) in comparison with the control transfectants. 

The levels of the control cells established by transfecting the parental PC3M cells with plasmid DNA alone and 10 separate RNAi transfected clones isolated from the joint transfection of molecules 1 and 2 were shown Figure x (Vasso: if possible, give the Western blot figures in the following space):










Figure 3.1.3. Western blot analysis of PKC- expression in patrental, control and siRNA-transfectant cells. The possible loading artifacts were corrected by incubating the same blot with antibody against -Actin. 


The levels of the control cells established by transfecting the parental Du145 cells with plasmid DNA alone and 10 separate RNAi transfected clones isolated from the joint transfection of molecules 1 and 2 were shown Figure y (Vasso: give the Western blot figures in the following space):

 Amongst the 10 transfectant clones, the levels of PKC- expression were reduced by ?-?% (or ?% to ?% of the level detected in the control cells), in comparison with the control transfectants. 

As shown in Figure 2.3.10, both RNAi transfectant clones DU145/ PKC--2/Si and DU145/ PKC--3/Si, which were originated from parental Du145 cells, exhibited a x- and y- fold reduction respectively in the level of PKC-, in comparison of the that in parental cells (Vasso: give exact numbers).







           (Vasso: give the Western blot result Chart here;)





3.1.4. The effect of suppressing the expression of PKC--3 on cell proliferation.


To investigate the effect of suppressing the expression of PKC--3 on cell proliferation, the in vitro proliferation assay was performed to assess the proliferation rate of the control transfectants and the RNAi transfectant clone PC3M-PKC--1/Si and DU 145-PKC--2/Si. To measure the proliferation rate of different cells, the same number of cells from each cell line was cultured in triplicate and counted each day for 15 (Vasso: 7 days would enough) days. The proliferation rats of each cells was shown in Figure  3.1.4. 




















Prostate cancer is a multistep process, accumulated by alterations in tumour-suppressor genes and dominant oncogenes. Increased activity of oncogenes defines autonomous deregulation of cells growth and tumour formation. Autonomous enhanced PKC- expression was associated with cancers of prostate, breast, skin, kidney, thyroid, blood, brain, and colon (Cornford P 1999, Lavie Y 1998, Marks F 1995, Reddig PJ 2000, Engers R 2000, Knauf JA 1999, Mayne GC 1998, Sharif TR 1999, Perletti GP 1998). In the present study using human prostate epithelial cell lines with a variety degree of malignancy we show by RT-PCR analysis that PKC- is abundant expressed at the RNA level in all prostate epithelial cells. Its protein expression level is increased in malignant cells, associated with malignant progression in prostate cell lines. In particular, the DU 145 and PC3M malignant prostate cells appear the maximum protein expression level, and hence PKC- might play an important role in prostate cancer development. 

Although the protein expression level of PKC- is not related with the degree of the malignancy. These results favouring the following hypothesis: First: PKC- through its actin binding motif at the C2 domain can binds actin regulated cytoskeleton rearrangement and cells morphogenesis suggesting that its expression appears to be cell morphology and specific phenotype. Second, variety stimuli including fatty acids, growth factors and hormones such as the androgen receptor can modulate PKC’s function. The androgen receptor regulates PKC’s activity both in vivo and in vitro (Gavrielides MV (​http:​/​​/​www.ncbi.nlm.nih.gov​/​sites​/​entrez?Db=pubmed&Cmd=Search&Term=%22Gavrielides%20MV%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstract​), 2006). Both PC3 and PC3M prostate malignant cells do not expressed androgen receptor, and have been characterized as androgen unresponsive. In addition the DU 145 cells restore androgen receptor function. Consequently PKC- overexpression might related to androgen receptor status in DU 145 cells. Third, it is plausible the DU 145 cells may have been derived from metastases that had grown, possibly via a selection process, to be relatively homogenous for PKC- positive cells. 

Tumour development is the major cause of morbidity and mortality in patients with prostate cancer. It is critical to identify oncogenes and understand how they are responsible for inducing specific aspects of the malignant phenotype, and to allow improvement of clinical detection and management. The inactivation of gene function by reverse genetics is important for elucidating gene function and could also have a great impact on the treatment of diseases initiated by aberrant gene expression. Among the employed strategies, the recently discovery of RNA interference has offered an additional way to inhibit the expression of virtually any gene in living cells. Therefore, to further investigate the biological significance of PKC- elevated level in malignant prostate cell lines its expression was suppressed by silence interference RNA technology. 

PKC- unique structure is comprised from two distinct functional domains, the regulatory and the catalytic domain. The regulatory domain is response to a second messenger and is important for its intracellular targeting and interactions with other proteins (Schechtman and Mochly-Rosen, 2001). The catalytic domain is responsible for PKC- regulation and its subcellular distribution. In this study, the design siRNA was silence at different points both the two PKC- domains. Transient transfectant high malignant PC3M prostate cells and DU 145 androgen independent cells, with one of the chosen siRNA targets only decline the PKC- protein level. It was not plausible to clarify the reason. It is likely that the efficacy of RNAi depends on the region where siRNA targets. Another possibility is that degradation rate of PKC- is too slow to see the reduction of its amount by Western blotting during time period of this investigation. Alternatively, a certain type of PKC may escape from the RNAi pathway conserved in prostate epithelial cells.  

Moreover, double transfection of the PC3M and DU 145 cells with the two siRNA targets signify the maximum PKC- inhibition. Western blotting analysis with phosphorylated PKC- antibody at position Ser729, shows that the enzyme abolishes complete its functional activity. Phosphorylation of PKC- at Ser729 is related with increased enzymatic activity and important for its proper intracellular localization and function. These results suggest that the siRNA technology is effective abolished PKC- activity in PC3M and DU 145 cells. 

Deregulated cell growth occurs as a result of perturbed signal transduction cellular signals that modulate or alter cellular behaviour or function (Hunter, T. 2000). In normal prostate gland, signalling needs to be precisely coordinated and integrated at all times, whereas the properly regulated differentiated signals are critical for preventing cells growth and oncogenesis. Therefore, to further analyse if the complete reduction of PKC- activity triggers the malignant androgen independent cellular growth the MTT proliferation assay was employed. The DU 145 and PC3M stable transfectant with siRNA as well as the control cells were culturing under the standard culture conditions as was described in section 2.1.3.i., and its growth properties were monitoring for up to seven days. Present study results provides several independent lines of evidence supporting the hypothesis that PKC- expression may be sufficient to maintain prostate cancer growth and survival. 

It has been reported that activation of PKC- in prostate malignant cell lines modulate downstream effectors molecules such as mitogen-activated protein kinases, c-Myc, and caveolin-1and contribute to malignant transformation (Wu D 2002a, 2002b). Force PKC- expression in prostate LNCaP cells and CWR22 xenografts was sufficient to confer Bax conformational rearrangements that are important for Bax oligomerization, mitochondrial integration, and cytochrome c release (McJilton MA (​http:​/​​/​www.ncbi.nlm.nih.gov​/​sites​/​entrez?Db=pubmed&Cmd=Search&Term=%22McJilton%20MA%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstract​) 2003. Considered these lines of results in their entirety were put forward the notion that an association of PKC- with Bax may neutralize apoptotic signals propagated through a mitochondrial death-signalling pathway. 
Furthermore, the complex signalling network operating downstream of PKC- energetically advances the survival and proliferation of prostate cancer cells. Studies in adherent prostate cancer cells demonstrated that a mutually reinforcing signalling loop sustained by the activation of beta1 integrins, PKC-, and PKB/Akt (Wu D 2004). Activation of PKB/Akt is correlated with proliferation in human prostate tumours as estimated by the expression of the cell proliferation antigen Ki67 (Ghosh PM (​http:​/​​/​www.ncbi.nlm.nih.gov​/​sites​/​entrez?Db=pubmed&Cmd=Search&Term=%22Ghosh%20PM%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstract​), 2005). 
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